In the management of RA-ILD, we are in a curious situation where we have become polarised in two different directions: aggressive treatment of all patients with combination therapies of biologic agents and anti-fibrotic drugs, or a “wait and see” approach. It is in this setting that the results of Abstract 0448 piqued my interest.
All News
Article
Article
Eosinophilic granulomatosis with polyangiitis (EGPA) is the rarest of the ANCA-associated vasculitides. Compared to GPA and MPA, EGPA carries a mechanistically unique pathophysiology involving eosinophil-mediated inflammation.
Article
Every rheumatologist knows this patient. Her ASDAS is 3.4. Her CRP is normal, her MRI is quiet, and she is on her third biologic. The reflex is to reach for a fourth. Abstracts from ACR Convergence 2026 make a quietly radical case against this reflex.
Article
ACR Research Highlights Pediatric Treatment Gaps, Criteria Performance, and Early Promise of CAR T-Cell Therapy
ACR Press Release
New research presented at ACR Convergence 2026 examines pediatric patient’s symptoms and potential therapies that can assist children and adolescents with symptom control, as research, medication and therapies are currently limited.
sheila
Tweet
RCT of Sirolimus 1.5mg/day for active SLE:
Sirolimus (54.3%) showed improvement of SRI4 respose at wk 24 vs. PBO, incl improvement in C3, C4
More AEs seen in SIR arm: dyslipidemia, cytopenias, menstrual changes
Limitations: short pd 24wks, limited cntrs
@RheumNow #ACR26 ABS0874 https://t.co/14W6X7mxi6
Akhil Sood MD, MS
Tweet
Does retatrutide improve knee OA?
Abs 0871: Phase 3, trial
At Week 68: Retatrutide 9 mg / 12 mg / placebo:
• WOMAC pain ↓4.48 / 4.41 / 2.43 points
• Weight ↓26.4% / 28.7% / 2.1%
More on retatrutide achieved ≥50% improvement in WOMAC pain & physical function.
#ACR26 @RheumNow https://t.co/Nt1L5WeYVX
Brian Jaros, MD
Tweet
We should be using steroid-sparing therapy in PMR EARLY!!
Analysis of SAPHYR: better response to Sarilumab compared to PBO extinguished in patients with disease longer than a year
A similar trend was observed in a comparative real world data set
Abst0167 @Rheumnow #ACR26 https://t.co/OO5Nv3DJZd
David Liew
Tweet
With bDMARD taper, surely we need predictive biomarkers to go forward
OPTIBIO trial🇪🇸 first 2y
Biomarkers (VSIG4, anti-IFNg) actually predicts flare better than baseline DAS28
(and porque no los dos)
We need to see more of this
ABST0131 #ACR26 @RheumNow
https://t.co/auAg5wl2CD https://t.co/Oktu1TNVSL
Litifilimab (anti-BDCA2) in CLE: CLASI-70 gains kept building to wk 52
Ph2 AMETHYST Part A, n=59 vs 34 PBO
Wk 16: 22.5% vs 5.7%
Wk 24: 21.7% vs 5.8%
Wk 52: 28.8% on drug, 35.4% after PBO switch
Secondary endpoints, nominal p. Phase 3 decides.
@RheumNow #ACR26 Abstr#P0872 https://t.co/qpNyKIi31v
Newer SLE Rxs, SRI-4 delta vs PBO:
Telitacicept 34
Obinutuzumab 24
Dapirolizumab pegol 19
Anifrolumab 16
Belimumab 14
Cross-trial data with different PBO rates and populations. Choose by organ involvement and phenotype.
Liana Fraenkel, Year in Review
@RheumNow #ACR26 https://t.co/dB5cbfsEWj
Eric Dein
Tweet
Yr in Rvw #ACR26
Retraction of Avacopan ADVOCATE trial due to post hoc re-adjudication endpoints after database lock/unblinding
FDA investigation
@RheumNow https://t.co/XvoInbGXs9
Eric Dein
Tweet
Yr in Rvw #ACR26
Telitacicept - BLyS and APRIL
P3DBRCT in China for active SLE
SRI-4 response 67 vs 33 in PBO, GC sparing
But P3 program outside of China terminated
@RheumNow https://t.co/8B42jbz9Yl
sheila
Tweet
YIR: Retatrutide for Knee OA w/ WOMAC pain 4-9 and KL 2&3:
Retatrutide vs PBO showed decr in WOMAC pain scores.
Hormone receptor agonists work in knee OA but mechanism is still unclear.
@RheumNow #ACR26 https://t.co/CWLUAoUqJ3
Eric Dein
Tweet
Yr in Rvw #ACR26
Obinitizumab, Furie NEJM 2026
P3DBRCT for active SLE
SRI-4 response 77 vs 53 PBO, GC sparing at wk 52
DORIS remission 34 v 14
Increase serious ifn 9% vs 5% in PBO
@RheumNow https://t.co/PGpBc3HPTE
Eric Dein
Tweet
Yr in Rvw #ACR26
Low dose belimumab 120 mg, Ann Rheum Dis 2026
Study in low disease activity SELENA-SLEDAI
Flare within 52 wks, study stopped early 2/2 COVID
Possible option for lower BEL dose
@RheumNow https://t.co/8uSW8VXTyP
Eric Dein
Tweet
Yr in Rvw #ACR26
Sotatercept in PAH, activin-signaling inhib. Decr excess prolif PA smooth musc cells NEJM 2025
Stopped early 2/2 equipoise
77% less risk of clinical wors, +40 wk event-fr surv, 70% more likely to impr WHO fxnal class
Watch: polycythemia, pericardial eff
@RheumNow https://t.co/prV8L5QnWQ
Eric Dein
Tweet
Yr In Review #ACR26
Obexelimab Della-Torre NEJM
CD19 and FcyRIIb, Non-B cell depleting (unlike inebilizumab)
P3DBRCT, 52 wks 250 mg v PBO
28% flare diff vs PBO (compare to 50% in INE)
Less serious ifn than PBO
@RheumNow https://t.co/wEcO1Io03b
David Liew
Tweet
For RA TNFi-IR rotating to non-TNFi bDMARD, are you better off with abatacept or tocilizumab?
SUNSTAR H2H open label RCT 🇫🇷n=224
initial response (CDAI w26) same
drug survival better on toci (response, not AE)
We remain blessed with good bDMARDs in RA
ABST0468 #ACR26 @RheumNow https://t.co/4UoP6G9bgW
sheila
Tweet
YIR: This study fr Dr. W Robinson show that activated-naive autoreactive B cells expand before clinical arthritis
Clinical implications? Potential target for RA prevention.
@RheumNow #ACR26 https://t.co/uIG3kTIBzV
